転移性乳がんの日本人患者におけるラパチニブとカペシタビンの併用療法

基本情報

NCT ID

NCT00477464

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

51

治験依頼者名

GlaxoSmithKline

概要

This study is to evaluate the safety and efficacy of lapatinib taken together with capecitabine in Japanese patients. The study will proceed in two phases; the first phase(Part1) will lead to an evaluation of the mainly tolerability as well as PK parameters. If there are no major safety concerns in Part 1, the study will move into the second phase (Part 2) to further evaluate the safety and clinical activity.

対象疾患

介入

依頼者（Sponsor）